News | October 21, 2007

Drug-Eluting Stent Outperforms Bare Metal Says Study

October 22, 2007 - Implantation of the CYPHER Sirolimus-eluting Coronary Stent by Cordis Corp. used to treat completely blocked coronary arteries led to substantial reductions in recurrent blockage and the need for repeat treatment compared to bare metal stents in a study presented today at the Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007).

Researchers reported that the Approaches to Chronic Occlusions with Sirolimus-eluting Stents (ACROSS-CYPHER) study met its primary endpoint, which was the assessment of angiographic restenosis at six-month follow-up. Among 200 patients treated with the CYPHER Stent following successful reopening of a completely blocked coronary artery (chronic total occlusion), the likelihood of renarrowing of the treated segment (angiographic restenosis) was reduced by 65.6 percent compared with a pre-specified cohort of patients treated with a bare metal stent in the earlier Total Occlusion Study of Canada (TOSCA-1) trial. In the entire segment treated with balloon angioplasty and stents, the restenosis rate for the CYPHER Stent was 19.0 percent while the restenosis rate for the bare metal stent was 55.2 percent. Following risk adjustment, these differences translated into an 84 percent reduction in the primary endpoint (p

“Chronic total occlusions remain one of the most challenging lesions to treat, especially because rates of restenosis and reocclusion have remained high despite treatment with bare metal stents,” said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation, who presented the results. “These data, combined with the results of the PRISON II Randomized Controlled Trial, which showed similar positive results for the CYPHER Stent in chronic total occlusions, add to the unsurpassed volume of clinical evidence on the use of the CYPHER Stent in a variety of patients and lesion subsets, including these very complex, chronically occluded vessels.”

Among patients treated with the CYPHER Stent, at six months, there were no deaths, and myocardial infarction and target lesion revascularization occurred in 1.0 percent and 6.0 percent of patients, respectively. Overall major adverse cardiac events were similarly low, at 6.5 percent.

The reported stent thrombosis rate for the CYPHER Stent was 0.0 percent within 24 hours after stent implantation, 0.0 percent between 1 and 30 days after stent implantation; and 0.5 percent beyond 30 days after stent implantation.

The ACROSS-CYPHER Trial is a prospective, multi-center, open-label, single-arm study designed to demonstrate the safety and efficacy of the CYPHER Stent in non-acute chronic total occlusions. The study included patients from 15 medical centers in the United States and Canada.

Dr. Kandzari is one of the principal investigators of the Cordis-sponsored study. Enrollment and six-month follow-up were completed before Dr. Kandzari joined Cordis. At the time, Dr. Kandzari was part of the faculty at Duke University Medical Center.

In the United States, the CYPHER Stent is indicated for de novo lesions less than 30 mm in length in native coronary arteries between 2.5 mm and 3.5 mm in diameter. It does not have an approved indication for patients with chronic total occlusions.

For more information: www.cypherstent.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init